Dr Reddy's Laboratories Share Price (DRREDDY)
Check the latest share price of Dr Reddy's Laboratories, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 15 Jul 2025
NSE
Dr Reddy's Laboratories Stock Performance
Get live Dr Reddy's Laboratories share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,241Day's Price Range₹1,264.552 Week's Low
52 Week's High
₹1,02052-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | -7.14 % |
| 3 Month Return | + 8.29 % |
| 1 Year Return | -7.97 % |
| 3 Year Return | + 37.55 % |
| 5 Year Return | + 54.91 % |
| Market Stats | |
| Previous Close | ₹1,254.00 |
| Open | ₹1,254.80 |
| Volume | 11.84L |
| Upper Circuit | ₹1,375.60 |
| Lower Circuit | ₹1,125.60 |
Dr Reddy's Laboratories Fundamentals & Key Indicators
Check Dr Reddy's Laboratories market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹1,04,372.80 Cr
Return on Equity (ROE)
20.15
PE Ratio (TTM)
18.42
Return on capital employed (ROCE)
25.47
Industry PE ratio
51.74
Beta (LTM)
0.61
P/B Ratio
3.31
Dividend Yield
0.7
PEG Ratio
21.83
Quarterly Earnings Growth YOY
21.14
EPS (TTM)
68.65
Sector
Pharmaceuticals
Book Value
402.27
Technical Analysis
Bearish
View Technical Analysis
How to invest in Dr Reddy's Laboratories?
Investing in Dr Reddy's Laboratories is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Dr Reddy's Laboratories or DRREDDY on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Dr Reddy's Laboratories or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Dr Reddy's Laboratories with just a few clicks!
Dr Reddy's Laboratories Stock's Interest Amongst Investors
Dr Reddy's Laboratories Valuation
Track how Dr Reddy's Laboratories P/E has moved over time to understand its valuation trends.
Dr Reddy's Laboratories in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (18.42x)
July 14, 2025
Industry (51.74x)
July 14, 2025
Highest (53.88x)
December 18, 2020
Today’s Price to Earnings Ratio: 18.42x
Dr Reddy's Laboratories Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Dr Reddy's Laboratories.
based on 38 analysts
39.47%
Buy
23.68%
Hold
36.84%
Sell
39.47% of analysts recommend a 'HOLD' rating for Dr Reddy's Laboratories. Average target price of ₹1261.72
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Share Price Target
Get share price movements and forecasts by analysts on Dr Reddy's Laboratories.
Dr Reddy's Laboratories price forecast by 38 analysts
Upside of0.89%
High
₹1575
Target
₹1261.72
Low
₹969
Dr Reddy's Laboratories target price ₹1261.72, a slight upside of 0.89% compared to current price of ₹1260.9. According to 38 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:7.39%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Financial Results
Get the annual and quarterly financial summary of Dr Reddy's Laboratories, including revenue, profit, loss and more.
Indices Featuring Dr Reddy's Laboratories Stock
Check stock indices that include Dr Reddy's Laboratories.
Dr Reddy's Laboratories Earnings and Dividends
View detailed summary of the earnings and dividend history of Dr Reddy's Laboratories.
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit jumped 21.64% since last year same period to ₹1,593.30Cr in the Q4 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.7% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2025
In the quarter ending March 2025, Dr Reddys Laboratories Ltd has declared dividend of ₹8.00 - translating a dividend yield of 0.64%.
Read More about Dividends
Dr Reddy's Laboratories Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Dr Reddy's Laboratories.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | 0.00 | |
| Foreign Institutions | 25.75% | 0.00 | |
| Mutual Funds | 12.88% | 0.00 | |
| Retail Investors | 10.15% | 0.00 | |
| Others | 24.57% | 0.00 |
Dr Reddy's Laboratories vs Peers
Compare market cap, revenue, PE, and other key metrics of Dr Reddy's Laboratories with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 1,04,372.80 | 10.98% | 0.56 | 5,725 | 32,643 | |
| HOLD | 1,79,947.88 | 40.92% | 0.50 | 1,600 | 7,845 | |
| BUY | 1,15,232.11 | 36.92% | 0.64 | 1,911 | 11,516 | |
| BUY | 50,684.29 | -2.15% | 0.58 | 1,297 | 14,755 | |
| HOLD | 31,132.37 | 0.77% | 0.50 | 772 | 5,664 |
Dr Reddy's Laboratories News & Key Events
Latest news and events in one place to help you make informed investing decisions in Dr Reddy's Laboratories.
Dr. Reddys Faces Revenue Challenges Ahead - 14 Jul, 2025
Dr. Reddys Laboratories is expected to experience a transition year in FY26 due to declining revenues from gRevlimid. Morgan Stanley maintains an Equal-weight rating with a target price of ₹1,298, noting potential upside from semaglutide ramp-up.Dr. Reddy's Laboratories Announces Dividend Amid Market Concerns - 09 Jul, 2025
Dr. Reddy's Laboratories is set to pay a final dividend of ₹8 per share for FY25, with July 10 as the record date. Analysts express concerns over potential margin compression due to US tariffs and thin margins in generics. The stock is under scrutiny as investors rush to qualify for the dividend.Dr Reddys Downgraded by Macquarie to Neutral - 08 Jul, 2025
Macquarie has downgraded Dr Reddys Laboratories to Neutral from Outperform, reducing the target price from ₹1,450 to ₹1,190, citing competitive pressures on gRevlimid.Dr Reddy's Faces US Market Challenges Ahead - 02 Jul, 2025
Dr Reddy's Laboratories is preparing for increased competition in the US market, expecting a sales dip in FY26. The company plans to enhance its core business and pursue strategic growth initiatives. Meanwhile, the stock has seen a decline, slipping for five consecutive sessions, currently trading at Rs 1267.7.Dr. Reddy’s Laboratories AGM and Financial Updates - 01 Jul, 2025
Dr. Reddy’s Laboratories announced its 41st AGM for July 24, 2025, while the stock showed slight decline amid high trading volume. The company released its Integrated Annual Report, showcasing strong financial performance and a favorable analyst rating.Dr. Reddy's Shares Decline on Citi's Downgrade - 26 Jun, 2025
Dr. Reddy's Laboratories shares fell 2% after Citi Research maintained a sell rating and reduced its target price to Rs 990, highlighting concerns over growth, particularly in the Canadian GLP-1 market and declining Revlimid sales. The brokerage anticipates significant earnings drag and challenges in the upcoming generic Semaglutide launch.Dr Reddy's Shares Show Monthly Gains Amid Board Meeting - 25 Jun, 2025
Dr Reddy's Laboratories shares have increased by 7.75% over the past month. A Board meeting is set for July 23 to review financial results, while technical indicators suggest potential weakness in the stock's performance.Dr. Reddy's Gains USFDA Approval for Parkinson's Drug - 23 Jun, 2025
Dr. Reddy’s Laboratories announced tentative USFDA approval for its Parkinson's disease treatment, Carbidopa and Levodopa capsules. The company also plans a board meeting to review financial results.Dr Reddy's Expands US Manufacturing Amid Tariff Concerns - 21 Jun, 2025
Dr Reddy's Laboratories, through its subsidiary Aurigene, is enhancing its CDMO capabilities while planning to launch 15-20 new products annually in the US. The company is considering local manufacturing to mitigate tariff risks, as 42% of its revenue comes from the US market.Dr. Reddy's Laboratories Announces Key Developments - 20 Jun, 2025
Dr. Reddy's Laboratories received a target price increase from Bank of America, announced tax deductions on dividends, and scheduled investor meetings to enhance transparency.Dr Reddy's Allots Equity Shares to Employees - 16 Jun, 2025
Dr Reddy's Laboratories has allotted 57,885 equity shares of Re. 1 each to eligible employees as part of their Stock Options Scheme on June 14, 2025.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 1.25K Cr → 1.59K Cr (in ₹), with an average increase of 11.2% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 5 quarters, 7.31K Cr → 9.05K Cr (in ₹), with an average increase of 5.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 11.14% to 12.89% in Mar 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Mar 2025 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 26.85% to 25.75% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, DRREDDY stock has moved down by -7.1%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.22% to 10.15% in Mar 2025 quarter
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Revenue: ₹8,506.00Cr as on March 2025 (Q4 FY25)
Net Profit: ₹1,586.70Cr as on March 2025 (Q4 FY25)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddys Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | K Satish Reddy |
| E-voting on shares | Click here to vote |
Mutual Funds that own Dr Reddy's Laboratories
Check out the Mutual Funds with significant holdings in Dr Reddy's Laboratories.
FAQs
What is Dr Reddy's Laboratories share price today?
Dr Reddy's Laboratories share price today stands at ₹1260.9, Open: ₹1254.8, Previous Close: ₹1254, High: ₹1264.5, Low: ₹1241, 52 Week High: ₹1421.49, 52 Week Low: ₹1020.
What is today's traded volume of Dr Reddy's Laboratories?
Today's traded volume of Dr Reddy's Laboratories is 11.84L. Which means that 11.84L shares of Dr Reddy's Laboratories were bought and sold on the stock market during today's trading session.
What is Dr Reddy's Laboratories's market cap today?
Today's market capitalisation of Dr Reddy's Laboratories is ₹1,04,372.80 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Dr Reddy's Laboratories?
Dr Reddy's Laboratories’s 52 week high is ₹1421.49 and 52 week low is ₹1020. The current share price of Dr Reddy's Laboratories is ₹1260.9, which is -11.30% down from its 52 week high and 23.62% up from its 52 week low.